Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Here's Why Pediatrix Medical Can Be a Smart Addition to Your PortfolioPhoto, wide shot, wide-angle lens,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio

Pediatrix Medical Group, Inc. MD is a physician services provider company that offers a range of services across various specialties, including obstetrics, maternal-fetal medicine and neonatology

CoreWeave's $35-$39B Capex Plan: Can AI Demand Justify the Spend?Photo, wide shot, wide-angle lens,  Computer hardware manufacturer, Midday, harsh overhead sunlight, directional sunlightt, photo by Marc Adamus: https://img.theapi.app/temp/ec495607-1e17-40ee-a41d-7726313a9707.png
CoreWeave's $35-$39B Capex Plan: Can AI Demand Justify the Spend?

CoreWeave (CRWV is aggressively expanding its AI infrastructure to meet increasing customer demand, necessitating massive capacity additions. 2026 capital expenditures are now projected to be

What Makes Loma Negra Compania Industrial Argentina (LOMA) a New Buy StockPhoto, wide shot, wide-angle lens,  Janitorial service, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/4d4e885c-79e9-4b8f-bd91-e9721cd7c2e9.png
What Makes Loma Negra Compania Industrial Argentina (LOMA) a New Buy Stock

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics ALLO incurred a second-quarter 2026 loss of 13 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents. Lower research and development (R&D) spending

Can Asceniv Help ADMA Stock Combat IG Market Challenges?
Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at